CD19 and B-cell non-Hodgkin lymphoma: In a clinical trial, Brudno et al., have assessed the safety, feasibility, anti-lymphoma activity and immunogenicity of a second-generation fully human anti-CD19 CAR T cells (Hu19-CD828Z) in 20 patients with B-cell lymphoma.